Sandoz Group Partners with mAbxience to Develop Hemophilia Biosimilar

01:55 AM EDT, 09/18/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) agreed with biopharmaceutical company mAbxience to develop a biosimilar version of Hemlibra, or emicizumab, a treatment for hemophilia A. The Swiss drugmaker said Friday it will have exclusive global commercialization rights for the proposed emicizumab biosimilar, excluding Argentina, Uruguay, and Paraguay, while mAbxience will handle development and manufacturing.